Search for a trial

A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 Monotherapy and Combination Therapy in Subjects with Lymphoid Malignancies

To determine appropriate dosing regimens for use in future clinical trials of GS 9820 in subjects with lymphoid malignancies.

screening for coronary disease after mediastinal irradiation in Hodgkin Lymphoma survivors

Primary objectives:1: To determine whether CT- coronary angiography by MSCT as a screening method of HL survivors treated with mediastinal irradiation accurately identifies asymptomatic significant coronary artery disease. 2: To establish the…

Late effects: Insights into Cardiovascular disease risk after Hodgkin's lymphoma Treatment

The aim of this study is to identify risk factors for various CVDs, i.e. to quantify separate and joint effects of radiation dose to the heart, anthracycline dose, other CT, life style factors, established CVD risk factors and genetic susceptibility…

A Phase I/II Study of brentuximab vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Primary• To assess the safety profile and determine the pediatric maximum tolerated dose and/or recommended phase 2 dose of brentuximab vedotin• To assess the pharmacokinetics of brentuximab vedotin• To determine the overall response rate (complete…

Monitoring of TARC and MDC in blood as tool to evaluate disease activity in patients with Hodgkin Disease

The aim of this project is a prospective study of blood samples of HL patients to determine the value sensitivity and specificity of increase TARC an MDC serum levels for the early detection of a relapse.

Quality of life and health care utilisation among survivors of
Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma.

The objective of this study is to measure quality of life, health care use and morbidity (like fatigue, anxiety and depression) of patients diagnosed at least 2 years ago. These variables will be compared between the different treatment modalities…

The effect of treatment on fertility parameters in children with Hodgkins' Lymphoma

To respectively evaluate the fertility parameters before and after treatment for pediatric HL in the Netherlands according to the COG protocols for low risk, intermediate risk and high risk, to test the hypothesis that these protocols will not harm…

Whole-body MRI for initial staging, early response assessment and restaging after completion of therapy in pediatric Hodgkin lymphoma.

The aims of this study are to compare the diagnostic performance of whole-body MRI (including DWIBS) to FDG-PET/CT and/or CT for the initial staging, early response assessment and restaging after completion of therapy in children with Hodgkin*s…

A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL)

Primary objectives:(1) To determine the safety and tolerability of pembrolizumab. (2) To evaluate the Overall Response Rate (ORR) of pembrolizumab by independent central review according to the International Working Group (IWG) response criteria (…

A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma

PrimaryPhase 1-To characterize the safety and tolerability of isatuximab in combination with cemiplimab in participants with relapsed and refractory cHL, DLBCL or PTCL, and to confirm the recommended Phase 2 dose (RP2D).Phase 2- Cohort A1 (anti-…

A Phase 1 trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies.

Main objective:1. To estimate the Overall Response Rate (ORR) and the clinical benefit rate in selected cohorts of patients with hematologic malignancies,separately for each cohort2. To evaluate the safety of the selected dose regimes in an expanded…

Role of genomic factors on late adverse events after lymphoma

Our main objective is to dissect the genomic determinants of treatment-related adverse events after lymphoma, specifically cardiovascular disease and second malignant neoplasms. As such, we will assess the association of genetic and epigenetic…

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475
(Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin
Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE
667).

This study has been transitioned to CTIS with ID 2023-504821-38-00 check the CTIS register for the current data. Goal of this study is to determine the optimal balance between maintaining high rates of OS in this group and avoiding the long-term…

AERN study: Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trial

The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL previously treated with an anti-PD1 antibody. Primary objective of the trial is to show efficacy of the experimental treatment strategy.Secondary…

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of
Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or
Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2023-503715-14-00 check the CTIS register for the current data. Part A: To characterize the safety, tolerability, and define the MTD or RP2D for the combination of relatlimab + nivolumab in pediatric…

Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response.

There are two treatment groups in this study: one with participants at low risk of deterioration and one with participants at standard risk of deterioration. The primary objective for each group is described below.-Low Risk group: To describe the…

Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma

This study has been transitioned to CTIS with ID 2024-511151-18-00 check the CTIS register for the current data. • Determine a feasible 89Zr-brentuximab-PET imaging schedule, to allow assessment of the biodistribution of 89Zr-brentuximab in tumor…

Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab
(BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous
Stem Cell Transplant (ASCT)

The main research question is whether or not the administration of nivolumab increases "overall response rate" (ORR) in patients with classical Hodgkin Lymphoma who have progressed or relapsed following autologous stem cell transplant (…

AN EARLY PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS

Safety ObjectiveThe safety objective for this study is as follows:* To evaluate the safety and tolerability of atezolizumab in pediatric and young adult patients, focusing on the nature, frequency, and severity of serious and non-serious adverse…

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in
Participants With Advanced Solid Tumors

Primary Objective part A:* To evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered BIW in subjects withadvanced solid tumors* To determine the MTD and/or RP2D of single-agent M4344 administered BIW in…